vesitirim 1 mg/ml oral suspension
astellas pharma co. limited - solifenacin succinate - oral suspension - 1 milligram(s)/millilitre - drugs for urinary frequency and incontinence; solifenacin - urologicals, drugs for urinary frequency and incontinence - symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome.
vesitirim 5 mg film-coated tablets
astellas pharma co. limited - solifenacin succinate - film-coated tablet - 5 milligram(s) - drugs for urinary frequency and incontinence; solifenacin
vesitirim 10 mg film-coated tablets
astellas pharma co. limited - solifenacin succinate - film-coated tablet - 10 milligram(s) - drugs for urinary frequency and incontinence; solifenacin
omnexel®, 400 micrograms prolonged release tablets, film-coated
astellas pharma co. limited - tamsulosin hydrochloride - prolonged-release tablet - 400 microgram(s) - alpha-adrenoreceptor antagonists; tamsulosin
vesomni 6 mg/0.4 mg modified-release tablets
astellas pharma co. limited - solifenacin succinate; tamsulosin hydrochloride - modified-release tablet - 6 mg/0.4 milligram(s) - drugs for urinary frequency and incontinence; solifenacin
prograf 5 mg hard capsules
astellas pharma co. limited - tacrolimus - capsule, hard - 5 milligram(s) - calcineurin inhibitors; tacrolimus
prograf 1 mg hard capsules
astellas pharma co. limited - tacrolimus - capsule, hard - 1 milligram(s) - calcineurin inhibitors; tacrolimus
xtandi 40 mg
astellas pharma international b.v., israel - enzalutamide - capsules soft - enzalutamide 40 mg - enzalutamide - xtandi is indicated for:• the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc).• the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.• the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
xtandi 40 mg capsules
astellas pharma international b.v., israel - enzalutamide - capsules soft - enzalutamide 40 mg - enzalutamide - xtandi is indicated for:•the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc). •the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. •the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.• the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy
prograf 0.5 mg hard capsules
astellas pharma co. limited - tacrolimus - capsule, hard - 0.5 milligram(s) - calcineurin inhibitors; tacrolimus